

Reference FOI202223/147

Number:

From: Private Individual

Date: 29 June 2022

Subject: Number of cancer patients treated with Dabrafenib + Trametinib

Q1 Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:

a. Metastatic Melanomab. Adjuvant Melanomac. mutated Lung Cancer

A1 a-c: Zero. We have not had any patients with the diagnosis listed